NCT06873204
Impact of Soluble Arabinoxylan and Rice Bran Fiber on the Gut Microbiome in Healthy Adults
Not Yet Recruiting
NAAges 18–45InterventionalBasic sciencePurdue UniversityInvestigator-initiated
~25 participants
Updated 2025-06-29 on ClinicalTrials.gov
What's tested:Soluble ArabinoxylanRice BranMaltodextrin (Placebo)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Comparison of two test fibers (insoluble cereal bran and soluble arabinoxylan) and a control (maltodextrin) on gut beneficial bacteria
Measured over From enrollment to the end of treatment at 13 weeks.
Conditions
Where it's being run
1 sites across 1 statesIndiana1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Men or women.
Aged between 18-45 years.
Body mass index between 18.5 and 25 kg/m².
Able to read/speak English.
Exclusion
Gastrointestinal disorders (inflammatory bowel disease, irritable bowel syndrome, gluten sensitivity/intolerance, etc.).
Those who took antibiotics 3 months before the study.
Individuals taking regular medication or supplements that might affect the gut microbiota.
Individuals undertaking weight-loss diets.
Unstable body weight (±3 kg in the past 3 months), and individuals below 110 lb.
Heavy drinkers (for men, consuming more than 4 drinks on any day or more than 14 drinks per week; for women, consuming more than 3 drinks on any day or more than 7 drinks per week).
Smokers (those who have smoked 100 cigarettes in their lifetime and who currently smoke cigarettes, even every day or occasionally).
Breastfeeding or pregnant women.
What this trial measures
- Comparison of two test fibers (insoluble cereal bran and soluble arabinoxylan) and a control (maltodextrin) on gut beneficial bacteriaFrom enrollment to the end of treatment at 13 weeks.
The primary outcome of the study is change in butyrogenic Clostridium cluster XIVa gut bacteria.